Callahan Advisors LLC Buys 94,846 Shares of Pfizer Inc. $PFE

Key Points

• Callahan Advisors LLC increased its stake in Pfizer Inc. by 16.5%, acquiring an additional 94,846 shares, bringing their total holdings to 670,343 shares valued at approximately $16.25 million.
• Several institutional investors, including Brighton Jones LLC and Wealth Enhancement Advisory Services LLC, significantly boosted their stakes in Pfizer, indicating a growing interest in the company.
• Pfizer announced a quarterly dividend of $0.43 per share, reflecting a strong annualized yield of 7.1%, as well as setting a target EPS guidance of 2.900-3.100 for FY 2025.

Callahan Advisors LLC boosted its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 16.5% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 670,343 shares of the biopharmaceutical company's stock after purchasing an additional 94,846 shares during the quarter. Pfizer comprises 1.5% of Callahan Advisors LLC's holdings, making the stock its 20th largest holding. Callahan Advisors LLC's holdings in Pfizer were worth $16,249,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors also recently added to or reduced their stakes in the company. Brighton Jones LLC boosted its holdings in Pfizer by 1,282.4% in the fourth quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company's stock worth $17,677,000 after acquiring an additional 618,117 shares in the last quarter. Revolve Wealth Partners LLC boosted its holdings in Pfizer by 12.5% in the fourth quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company's stock worth $498,000 after acquiring an additional 2,087 shares in the last quarter. GAMMA Investing LLC boosted its holdings in Pfizer by 69.0% in the first quarter. GAMMA Investing LLC now owns 63,131 shares of the biopharmaceutical company's stock worth $1,600,000 after acquiring an additional 25,785 shares in the last quarter. Wealth Enhancement Advisory Services LLC boosted its holdings in Pfizer by 55.3% in the first quarter. Wealth Enhancement Advisory Services LLC now owns 2,606,123 shares of the biopharmaceutical company's stock worth $66,039,000 after acquiring an additional 928,180 shares in the last quarter. Finally, Ritholtz Wealth Management boosted its holdings in Pfizer by 54.7% in the first quarter. Ritholtz Wealth Management now owns 51,799 shares of the biopharmaceutical company's stock worth $1,313,000 after acquiring an additional 18,309 shares in the last quarter. Institutional investors own 68.36% of the company's stock.

Analyst Ratings Changes

A number of equities research analysts recently commented on the company. Morgan Stanley decreased their target price on Pfizer from $33.00 to $32.00 and set an "equal weight" rating for the company in a report on Friday, October 10th. Bank of America lifted their target price on Pfizer from $28.00 to $30.00 and gave the stock a "neutral" rating in a report on Friday, October 3rd. UBS Group reaffirmed a "neutral" rating and set a $28.00 target price on shares of Pfizer in a report on Wednesday, October 1st. Citigroup lifted their target price on Pfizer from $25.00 to $26.00 and gave the stock a "neutral" rating in a report on Wednesday, August 6th. Finally, Weiss Ratings reaffirmed a "hold (c-)" rating on shares of Pfizer in a report on Wednesday, October 8th. Two investment analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, twelve have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Pfizer has an average rating of "Hold" and an average price target of $28.35.

Pfizer Trading Down 0.5%

Shares of NYSE:PFE opened at $24.39 on Thursday. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $29.82. The company has a market capitalization of $138.69 billion, a PE ratio of 12.98, a PEG ratio of 0.81 and a beta of 0.55. The business has a 50 day moving average of $24.89 and a two-hundred day moving average of $24.13. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The company had revenue of $14.65 billion during the quarter, compared to the consensus estimate of $13.43 billion. During the same period in the previous year, the company posted $0.60 earnings per share. Pfizer's revenue for the quarter was up 10.3% on a year-over-year basis. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, December 1st. Shareholders of record on Friday, November 7th will be issued a $0.43 dividend. The ex-dividend date of this dividend is Friday, November 7th. This represents a $1.72 dividend on an annualized basis and a yield of 7.1%. Pfizer's payout ratio is presently 91.49%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.